Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05877560 · ClinicalTrials.gov registry record · NA
Non-invasive Brain Stimulation for Treating Symptomatic Convergence Insufficiency
A NA study of Convergence Insufficiency, sponsored by Midwestern University.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT05877560 is a NA study of Convergence Insufficiency that is actively recruiting participants, run by Midwestern University. The registered enrollment target is 150 participants, above the 101-participant average among 6 other Convergence Insufficiency trials with a reported enrollment target (49% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05877560, a NA study of Convergence Insufficiency, is actively recruiting participants, sponsored by Midwestern University.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this randomized controlled trial is to test the effectiveness of non-invasive brain stimulation in treating adults with symptomatic convergence insufficiency compared to vergence/accommodative therapy. The main questions it aims to answer are: 1. Can non-invasive brain stimulation shorten the treatment time of office-based vergence/accommodative therapy for convergence insufficiency? 2. Is non-invasive brain stimulation alone just as effective as office-based vergence/accommodative therapy in treating convergence insufficiency? The investigators hypothesize that non-invasive brain stimulation will shorten the treatment time from 12 weeks to 8 weeks of office-based vergence/accommodative therapy and that non-invasive brain stimulation alone would be equally effective as office-based vergence/accommodative therapy in improving symptomatic convergence insufficiency. Participants will be randomized into one of three treatment groups: 1. Non-invasive brain stimulation with office-based vergence/accommodative therapy. 2. Sham stimulation with office-based vergence/accommodative therapy. 3. Non-invasive brain stimulation only. Researchers will compare baseline measurements of near point of convergence (NPC) and positive fusional vergence (PFV) to post-treatment measurements for each group.
Conditions Studied
Interventions
- DEVICE Anodal-Transcranial Direct Current Stimulation
- BEHAVIORAL Office-Based Vergence/Accommodative Therapy
- DEVICE Sham Transcranial Direct Current Stimulation
Study Locations (1)
Illinois
- Midwestern University Eye Institute - Downers Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-03-01 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05877560
The ClinicalTrials.gov registry entry for NCT05877560 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 101-participant average among 6 other Convergence Insufficiency trials with a reported enrollment target (49% higher). The listed sponsor is Midwestern University, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Convergence Insufficiency appearing as the primary indexed condition, and to 3 interventions - of which Anodal-Transcranial Direct Current Stimulation is the first listed.
NCT05877560 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05877560 about?
NCT05877560 is a clinical study titled "Non-invasive Brain Stimulation for Treating Symptomatic Convergence Insufficiency". The goal of this randomized controlled trial is to test the effectiveness of non-invasive brain stimulation in treating adults with symptomatic convergence insufficiency compared to vergence/accommodative therapy. The main questions it aims to answer are: 1. Can non-invasive brain stimulation short...
What is the current status of trial NCT05877560?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2025-03-01. Estimated completion is 2028-12-31.
What conditions does trial NCT05877560 study?
This clinical trial studies the following conditions: Convergence Insufficiency.
What interventions are being tested in trial NCT05877560?
The interventions under investigation include: Anodal-Transcranial Direct Current Stimulation (DEVICE), Office-Based Vergence/Accommodative Therapy (BEHAVIORAL), Sham Transcranial Direct Current Stimulation (DEVICE).
Who is sponsoring clinical trial NCT05877560?
This trial is sponsored by Midwestern University, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05877560 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Convergence Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Eye Recovery Automation for Post Injury Dysfunction (iRAPID)
RECRUITING · NA
-
Neural Mechanism of Vision Therapy for Patients With Convergence Insufficiency
COMPLETED · NA
-
Home-based Vision Therapy
RECRUITING · Phase 1
-
Effectiveness of Virtual Reality Vision Therapy - VERVE
RECRUITING · Early Phase 1
-
A Prospective Observational Study of Adult Strabismus
COMPLETED
-
Eyetracking and Neurovision Rehabilitation of Oculomotor Dysfunction in Mild Traumatic Brain Injury
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.